Potential of old-generation antibiotics to address current need for new antibiotics

被引:190
作者
Falagas, Matthew E. [1 ,2 ,3 ]
Grammatikos, Alexandros P. [1 ]
Michalopoulos, Argyris [1 ,4 ]
机构
[1] Alfa Inst Biomed Sci, Athens 15123, Greece
[2] Henry Dunant Hosp, Dept Med, Athens, Greece
[3] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
[4] Henry Dunant Hosp, Intens Care Unit, Athens, Greece
关键词
Acinetobacter baumannii; aminoglycoside; chloramphenicol; colistin; fosfomycin; fusidic acid; multiple-drug resistant; polymyxin B; Pseudomonas aeruginosa;
D O I
10.1586/14787210.6.5.593
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Despite the constantly increasing need for new antimicrobial agents, antibiotic drug discovery and development seem to have greatly decelerated in recent years. Presented with the significant problem of advancing antimicrobial resistance, the global scientific community has attempted to find alternative solutions; one of the most promising ones is the evaluation and use of old antibiotic compounds. Due to the low-level use of many of the old antibiotic compounds, these have remained active against a large number of currently prevalent bacterial isolates. Thus, clinicians are beginning to re-evaluate their use in various patient populations and infections, despite the fact that they were previously thought to be less effective and/or more toxic than newer agents. A number of old antibiotic compounds, such as polymyxins, fosfomycin, fusidic acid, cotrimoxazole, aminoglycosides and chloramphenicol, are re-emerging as valuable alternatives for the treatment of difficult-to-treat infections. The availability of novel genetic and molecular modification methods provides hope that the toxicity and efficacy drawbacks presented by some of these agents can be surpassed in the future.
引用
收藏
页码:593 / 600
页数:8
相关论文
共 70 条
  • [1] Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use
    Al-Aloul, M
    Miller, H
    Alapati, S
    Stockton, PA
    Ledson, MJ
    Walshaw, MJ
    [J]. PEDIATRIC PULMONOLOGY, 2005, 39 (01) : 15 - 20
  • [2] [Anonymous], 2007, CLIN INFECT DIS, DOI [10.1086/520991, DOI 10.1086/, DOI 10.1086/520991]
  • [3] Genetic manipulation of antibiotic-producing Streptomyces
    Baltz, RH
    [J]. TRENDS IN MICROBIOLOGY, 1998, 6 (02) : 76 - 83
  • [4] Chronobiology and chronotoxicology of antibiotics and aminoglycosides
    Beauchamp, Denis
    Labrecque, Gaston
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (9-10) : 896 - 903
  • [5] A SUGGESTED APPROACH TO ONCE-DAILY AMINOGLYCOSIDE DOSING
    BEGG, EJ
    BARCLAY, ML
    DUFFULL, SB
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (06) : 605 - 609
  • [6] Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance:: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model
    Bergen, Phillip J.
    Li, Jian
    Nation, Roger L.
    Turnidge, John D.
    Coulthard, Kingsley
    Milne, Robert W.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (03) : 636 - 642
  • [7] Bishara J, 2003, EMERG INFECT DIS, V9, P1168
  • [8] Anti-infective research and development - problems, challenges, and solutions
    Bradley, John S.
    Guidos, Robert
    Baragona, Steve
    Bartlett, John G.
    Rubinstein, Ethan
    Zhanel, George G.
    Tino, Michael D.
    Pompliano, David L.
    Tally, Frank
    Tipirneni, Praveen
    Tillotson, Glenn S.
    Powers, John H.
    Tillotson, Glenn S.
    [J]. LANCET INFECTIOUS DISEASES, 2007, 7 (01) : 68 - 78
  • [9] Natural products - The future scaffolds for novel antibiotics?
    Butler, MS
    Buss, AD
    [J]. BIOCHEMICAL PHARMACOLOGY, 2006, 71 (07) : 919 - 929
  • [10] Metaanalysis of short course antibiotic treatment for group a streptococcal tonsillopharyngitis
    Casey, JR
    Pichichero, ME
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (10) : 909 - 917